What are the main functions and efficacy of bichizumab?

Bimekizumab is a new generation of biological agents that belongs to the humanized IgG1 monoclonal antibody class. Its main therapeutic mechanism is to simultaneously target and neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). These two cytokines play a central role in the pathogenesis of a variety of chronic inflammatory diseases, especially plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Compared with previous drugs that only inhibit IL-17A, bichizumab provides stronger anti-inflammatory effects and more comprehensive disease control.

The main efficacy of bichizumab is its rapid clearance of plaque psoriasis. Studies have found that the drug can significantly improve patients' skin symptoms, including scales, erythema, and itching, in the early stages of treatment. Many patients can reach the clinical standard of PASI 90 or even PASI 100 before the 16th week, that is, the skin lesions are almost completely cleared. In addition to the significant improvement in skin manifestations, bichizumab also shows better control capabilities in psoriatic arthritis, etc. It can slow down joint inflammatory reactions, reduce pain and swelling, and improve patients' motor function and quality of life.

A distinctive pharmacological feature is its dual-target mechanism. IL-17F plays an important role in some patients, and simply inhibiting IL-17A may not be enough to completely control the disease. Bicizumab targets both IL-17A and IL-17F, improving the depth and breadth of anti-inflammatory efficacy. Because of this advantage, it is regarded as an "upgraded version" of IL-17 inhibitors and is an emerging drug option for the treatment of moderate to severe psoriasis.

Another significant benefit is its long-lasting effect. After completing the initial dose, bicizumab only needs to be injected once every 8 weeks (every 4 weeks for heavier patients). In clinical observations, most patients can maintain skin cleansing for a long time, which significantly reduces the patient's medication burden and improves compliance.

Reference materials:https://www.drugs.com/bimekizumab.html